Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Retina ; 41(6): 1242-1250, 2021 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-33079789

RESUMO

PURPOSE: To evaluate the clinical course of patients with neovascular age-related macular degeneration (nAMD) after developing endophthalmitis during their treatment with intravitreal injections. METHODS: Multicenter, retrospective series. RESULTS: From April 2013 to October 2018, 196,598 intravitreal anti-vascular endothelial growth factor (VEGF) injections were performed, with 75 cases of endophthalmitis (incidence 0.0381%). There was no association between intravitreal anti-VEGF drug (P = 0.29), anesthetic method (P = 0.26), povidone concentration (P = 0.22), or any intraprocedure variable and endophthalmitis incidence. Seventy-two patients (96%) were treated with intravitreal tap and inject , while 3 underwent immediate pars plana vitrectomy. After endophthalmitis resolution, 17 patients (22.7%) were not re-treated for nAMD (in 10 cases due to inactive disease; follow-up, 115 ± 8.4 weeks). Patients required less frequent anti-VEGF injections after infection (7.4 ± 0.61 weeks vs. 11.5 ± 1.8 weeks; P = 0.004). Preinfection logarithm of the minimum angle of resolution visual acuity was 0.585 ± 0.053 (∼20/77). It worsened with endophthalmitis (1.67 ± 0.08, ∼20/935; P < 0.001) and again on postendophthalmitis treatment day 1 (1.94 ± 0.064; count fingers; P < 0.001), but improved after reinitiating nAMD therapy (1.02 ± 0.11; ∼20/209; P < 0.001). Better visual acuity on postendophthalmitis week 1 (P = 0.002) and reinitiation of nAMD treatment (P = 0.008) were associated with better final visual acuity, and streptococcal culture with worse visual acuity (P = 0.028). The postendophthalmitis treatment interval was associated with the anti-VEGF drug used (aflibercept = ranibizumab > bevacizumab; P < 0.001). CONCLUSION: Patients with nAMD required fewer injections after endophthalmitis, suggesting a biological change in disease activity. Neovascular age-related macular degeneration became quiescent in 13.3% of eyes. Most achieved better outcomes with anti-VEGF reinitiation.


Assuntos
Inibidores da Angiogênese/administração & dosagem , Endoftalmite/etiologia , Medição de Risco/métodos , Degeneração Macular Exsudativa/tratamento farmacológico , Idoso , Idoso de 80 Anos ou mais , Inibidores da Angiogênese/efeitos adversos , Endoftalmite/epidemiologia , Feminino , Humanos , Incidência , Injeções Intravítreas/efeitos adversos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Fatores de Risco , Tomografia de Coerência Óptica/métodos , Estados Unidos/epidemiologia , Fator A de Crescimento do Endotélio Vascular/antagonistas & inibidores , Acuidade Visual , Degeneração Macular Exsudativa/diagnóstico
2.
Clin Infect Dis ; 38(4): 542-6, 2004 Feb 15.
Artigo em Inglês | MEDLINE | ID: mdl-14765348

RESUMO

Postoperative endophthalmitis remains a serious clinical problem in ophthalmology, with an incidence of approximately 0.5%. Prognosis is largely determined by the virulence of the offending organism. The Endophthalmitis Vitrectomy Study (EVS) was a prospective, randomized trial comparing various diagnostic and treatment modalities in cases of endophthalmitis that followed cataract surgery. The EVS found that vitrectomy was only beneficial for patients presenting with very poor visual acuity and that intravenous antibiotic treatments had no additional benefit, compared with intravitreal antibiotic therapy alone. However, weaknesses of the EVS leave these conclusions open to modification in the future. Preoperative application of povidone-iodine preparation to the skin and conjunctiva is the only proven endophthalmitis prophylaxis. Endophthalmitis may be chronic and may follow glaucoma surgery and intravitreal injection of gas and drugs. The EVS did not study these issues, although they are associated with specific features that may require alterations in patient management.


Assuntos
Endoftalmite/etiologia , Glaucoma/complicações , Procedimentos Cirúrgicos Oftalmológicos/efeitos adversos , Complicações Pós-Operatórias/microbiologia , Antibioticoprofilaxia , Doença Crônica , Endoftalmite/microbiologia , Endoftalmite/prevenção & controle , Glaucoma/cirurgia , Humanos , Complicações Pós-Operatórias/prevenção & controle
3.
Am J Ophthalmol ; 137(1): 196-8, 2004 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-14700675

RESUMO

PURPOSE: To describe a patient with central retinal artery occlusion successfully treated with neodymium:yttrium-aluminum-garnet laser arteriotomy and embolectomy. DESIGN: Interventional case report. METHODS: A 77-year-old woman noted sudden loss of vision after vigorous coughing. A central retinal artery occlusion was diagnosed. Four hours after symptoms appeared, arteriotomy and embolectomy with neodymium:yttrium-aluminum-garnet laser was performed. RESULTS: Displacement of embolus outside the artery with return of retinal perfusion and recovery of vision. Laser treatment also resulted in vitreous hemorrhage and false aneurysm formation of the central retinal artery. CONCLUSIONS: Neodymium:yttrium-aluminum-garnet laser arteriotomy in a patient with central retinal artery occlusion resulted in extrusion of the embolus, reopening of the central retinal artery, and return of vision. This technique warrants further study as a primary treatment for this blinding disorder.


Assuntos
Embolectomia/métodos , Terapia a Laser/métodos , Oclusão da Artéria Retiniana/cirurgia , Idoso , Falso Aneurisma/etiologia , Feminino , Angiofluoresceinografia , Humanos , Procedimentos Cirúrgicos Oftalmológicos , Complicações Pós-Operatórias , Artéria Retiniana/patologia , Oclusão da Artéria Retiniana/diagnóstico , Tomografia de Coerência Óptica , Acuidade Visual , Hemorragia Vítrea/etiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...